Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma

Table 2

In vitro effects of HDACIs on EC cell lines.

HDACI	Upregulatory effects	Downregulatory effects	Synergetic effects	References
Apicidin	Acetylated H3 and H4, p21, p27, E-cadherin, PARP, caspase-3, cytochrome c, Bax	Cyclin A, cyclin D1, cyclin E, CDK2, CDK4, p53, HDAC3, HDAC4, Bcl-2, 17β-hydroxysteroid-dehydrogenase type 1	n/a	[18, 36–38]
TSA	Acetylated H3, H4, and tubulin, p21, p27, miR-130b, DICER1, BIM, L1CAM, FOXA1, glycodelin, E-cadherin, PARP, caspase-3	Cyclin A, cyclin D1 and D2, MMP2, MMP9, DNMT3B mRNA, ERα, MCM7 mRNA, MYC, miR-106b-93-25	Aza-deoxycytidine: PR-B upregulation; High-glucose condition: degradation of CLDN-2; Paclitaxel: cell death induction	[26, 30, 31, 33, 40–50]
SAHA	Acetylated H3 and H4 bound to either Tig1 or C/ebpa gene, caspase-8 and caspase-9, glycodelin, FOXA1, E-cadherin, p21, p27, insulin-like growth factor-I receptor	Cyclin D1 and D2, Bcl-2, FLIP mRNA and protein levels, AURKA	n/a	[30, 40, 41, 53–58]
LBH589	PR mRNA, MIG6	MYC	Death receptor ligand TRAIL: cell death induction after knockdown of metadherin; Proteasome: overcomes the impact of gain-of-function p53 mutations	[32, 60–63]
NaB	Acetylated H3 and H4, p21, p27, ROS, phospho-p38 mitogen-activated protein kinase, γH2AX	ERα	Adriamycin: high human telomerase reverse transcriptase expression	[41, 42, 65–68]
VPA	E-cadherin	Bcl-2	VE465: PARP cleavage induction	[56, 70, 71]
OBP-801/YM753	n/a	n/a	LY294002: BIM increase with accumulation of ROS	[72]
Oxamflatin	PARP, caspase-8 and caspase-9	n/a	n/a	[15]
Scriptaid	Acetylated H3 and H4, p21, p27, E-cadherin	Cyclin A, Bcl-2	n/a	[75]
FK228	Acetylated H3 and H4, p21, p53, caspase-3, caspase-7, and caspase-8, PARP	n/a	n/a	[77]
PsA	Acetylated H3 and H4, p21	p53, pRb, cyclins, CDKs	n/a	[78]
MHY2256	p53	SIRT1 enzyme activity, SIRT protein levels, MDM2	n/a	[79]